Chapter 4 Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug disposition in obesity: toward evidence-based dosing.

  2015cited by this paper
• Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings

  2014cited by this paper
• Applied Pharmacometrics in the Obese Population

  2014cited by this paper
• Prevalence of childhood and adult obesity in the United States, 2011-2012.

  2014cited by this paper
• Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

  2014cited by this paper
• Recent national trends in the use of adolescent inpatient bariatric surgery: 2000 through 2009.

  2013cited by this paper
• Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

  2013cited by this paper
• Development and Validation of a Predictive Equation for Lean Body Mass in Children and Adolescents

  2012cited by this paper
• Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

  2012cited by this paper
• Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults

  2012cited by this paper
• Estimation of lean body mass in children.

  2011cited by this paper
• Chapter 2 Use of Percentiles and Z-Scores in Anthropometry

  2011cited by this paper
• Implications of Obesity for Drug Therapy: Limitations and Challenges

  2011cited by this paper
• Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

  2011cited by this paper
• Pharmacokinetics and drug dosing in obese children.

  2010cited by this paper
• Dosing dilemmas in obese children

  2010cited by this paper
• NONMEM User’s Guides. (1989–2009)

  2009cited by this paper
• Obesity in children and adolescents

  2009cited by this paper
• Impact of censoring data below an arbitrary quantification limit on structural model misspecification

  2008cited by this paper
• Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach

  2007cited by this paper
• Quantification of Lean Bodyweight

  2005cited by this paper
• The Single‐Dose Pharmacokinetics of Midazolam and Its Primary Metabolite in Pediatric Patients after Oral and Intravenous Administration

  2001cited by this paper
• Ways to Fit a PK Model with Some Data Below the Quantification Limit

  2001cited by this paper
• Clinical Pharmacology of Midazolam in Infants and Children

  1998cited by this paper
• Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers

  1992cited by this paper
• Effect of Age, Gender, and Obesity on Midazolam Kinetics

  1984cited by this paper

• Childhood obesity : Pharmacokinetic considerations for drugs used in the intensive care unit

  2019cites this paper
• Drug Dosing at the End of Life: a Pharmacometric Approach

  2018cites this paper